Psoriasis negatively affects patients’ quality of life. Secukinumab is a human interleukin-17A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis.
Objectives
The current analysis evaluated the benefits of secukinumab by assessing relationships between disease severity and patient-reported symptoms.
Methods
Correlations between psoriasis-related itching, pain, and scaling and disease severity scores (Psoriasis Area and Severity Index [PASI] and Investigator's Global Assessment [IGA]) were evaluated at baseline, Week 12, and change from baseline to Week 12 using secukinumab clinical data from ERASURE and FIXTURE. Symptom responder status and PASI/IGA change were evaluated using logistic modeling.
Results
Correlation coefficients ranged 0.11-0.49 for PASI and 0.19-0.52 for IGA. Greater PASI response was related to greater symptom response/complete relief.
Conclusions
Results further demonstrate the relationship between traditional clinical measures of disease severity and patient-reported, psoriasis-related itching, pain, and scaling –- hence the need to consider both outcomes together to evaluate treatment effects in this disease fully.
GudjonssonJ.E.JohnstonA.SigmundsdottirH.ValdimarssonH.. Immunopathogenic mechanisms in psoriasis.Clin Exp Dermatol Immunol.2004; 135: 1–8.
2.
ParisiR.SymmonsD.P.M.GriffithsC.E.M.AshcroftD.M.. Global epidemiology of psoriasis: a systematic review of incidence and prevalence.J Inv Dermatol.2013; 133: 377–85.
Van VoorheesA.FeldmanS.R.KooJ. (2009) The psoriasis and psoriatic arthritis pocket guide. [www document]. URL https://www.psoriasis.org/document.doc?id=354 [accessed on 15 July 2015].
5.
GottliebA.B.MathesonR.T.LoweN.A randomized trial of etanercept as monotherapy for psoriasis.Arch Dermatol.2003; 139: 1627–32.
6.
LebwohlM.G.BachelezH.BarkerJ.Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.J Am Acad Dermatol.2014 May; 70(5): 871–81. e1-30.
7.
RappS.R.FeldmanS.R.ExumM.L.FleischerA.B.Jr.ReboussinD.M.. Psoriasis causes as much disability as other major medical diseases.J Am Acad Dermatol.1999; 41: 400–7.
8.
FinlayA.Y.KhanG.K.. Dermatology Life Quality Index (DLQI) — a simple practical measure for routine clinical use.Clin Exp Dermatol.1994; 19: 210–6.
9.
MrowietzU.KragballeK.ReichK.Definition of treatment goals for moderate to severe psoriasis: a European consensus.Arch Dermatol Res.2011 Jan; 303(1): 1–10.
10.
StroberB.ZhaoY.TranM.H.Psychometric validation of the psoriasis symptom diary using phase 3 study data from patients with chronic plaque psoriasis.Int Soc Dermatol. Published online 30 October 2015. doi: 10.1111/ijd.13117.
11.
StroberB.GottliebA.B.ElewskiB.Item-level psychometric properties for a new patient-reported symptom diary.Value Health.2013; 16: 1014–22.
12.
RevickiD.A.WillianM.K.MenterA.SauratJ.H.HarnamN.KaulM.. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.Dermatology.2008; 216(3): 260–70.
13.
ToriiH.SatoN.YoshinariT.NakagawaH.; Japanese Infliximab Study Investigators. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.J Dermatol.2012 Mar; 39(3): 253–9.
14.
SilvaM.F.FortesM.R.MiotL.D.MarquesS.A.. Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment.An Bras Dermatol.2013 Sep-Oct; 88(5): 760–3.
15.
PoulinY.ShethP.GuY.TeixeiraH.D.. Health-related quality of life worsens disproportionately to objective signs of psoriasis after withdrawal of adalimumab therapy.Dermatol Ther (Heidelb).2014 Jun; 4(1): 33–42.
16.
KatugampolaR.P.LewisV.J.FinlayA.Y.. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.Br J Dermatol.2007 May; 156(5): 945–50.
WeismanS.PollackC.R.GottschalkR.W.. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis.J Dermatolog Treat.2003; 14: 158–65.
19.
LangleyR.G.FeldmanS.R.NyiradyJ.van de KerkhofP.PapavassilisC.. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.J Dermatolog Treat.2015 Feb; 26(1): 23–31.
20.
LangleyR.G.ElewskiB.E.LebwohlM.Secukinumab in plaque psoriasis: Results of two phase 3 trials.N Engl J Med.2014 Jul 24;371(4): 326–38.
21.
StroberB.SigurgeirssonB.PoppG.Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.Int J Dermatol.2016 Apr; 55(4): 401–7.
22.
CohenJ.. Statistical power analysis for the behavioral sciences, 2nd edn.Hillsdale NJ: Lawrence Erlbaum Associates; 1988.
StroberB.SigurgeirssonB.PoppG.Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept.JPPA.2016 Fall; 1(4): 167–175.
25.
SobellJ.M.FoleyP.TothD.Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis.Acta Derm Venereol.2016 May; 96(4): 514–20.
26.
DeshpandeP.R.RajanS.SudeepthiB.L.Abdul NazirC.P.. Patient-reported outcomes: A new era in clinical research.Perspect Clin Res.2011 Oct; 2(4): 137–44.
